A Phase IV open-label study to evaluate the safety and efficacy of 1mg/kg SQ administered efaluzimab in adults with bullous pemphigoid as a steroid sparing adjunctive treatment

(PI: Chen) Drug Support Only

Awarded By

  • Genentech

Contributors

Start/End

  • 2006 - December 2007